268 related articles for article (PubMed ID: 29991605)
21. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
[TBL] [Abstract][Full Text] [Related]
22. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
[TBL] [Abstract][Full Text] [Related]
23. Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants.
Kurtanović N; Tomašević N; Matić S; Mitrović MM; Kostić DA; Sabatino M; Antonini L; Ragno R; Mladenović M
Eur J Med Chem; 2022 Jan; 227():113869. PubMed ID: 34710747
[TBL] [Abstract][Full Text] [Related]
24. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
25. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
Singh K; Munuganti RSN; Lallous N; Dalal K; Yoon JS; Sharma A; Yamazaki T; Cherkasov A; Rennie PS
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462880
[TBL] [Abstract][Full Text] [Related]
26. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
27. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
28. A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.
Cipolletti M; Bartoloni S; Busonero C; Parente M; Leone S; Acconcia F
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805656
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer.
Wang Y; Min J; Deng X; Feng T; Hu H; Guo X; Cheng Y; Xie B; Yang Y; Chen CC; Guo RT; Dong C; Zhou HB
Acta Pharm Sin B; 2023 Dec; 13(12):4963-4982. PubMed ID: 38045063
[TBL] [Abstract][Full Text] [Related]
30. A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer.
Liu X; Hu Q; Wang W; Ma H; Pu J; Cui J; Gong T; Wu Y; Lu W; Huang J
Biochem Pharmacol; 2021 Jun; 188():114583. PubMed ID: 33915156
[TBL] [Abstract][Full Text] [Related]
31. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
33. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
34. Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells.
Nukatsuka M; Saito H; Noguchi S; Takechi T
In Vivo; 2019; 33(5):1439-1445. PubMed ID: 31471390
[TBL] [Abstract][Full Text] [Related]
35. A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers.
Pavlin M; Spinello A; Pennati M; Zaffaroni N; Gobbi S; Bisi A; Colombo G; Magistrato A
Sci Rep; 2018 Jan; 8(1):649. PubMed ID: 29330437
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Wardell SE; Yllanes AP; Chao CA; Bae Y; Andreano KJ; Desautels TK; Heetderks KA; Blitzer JT; Norris JD; McDonnell DP
Breast Cancer Res Treat; 2020 Jan; 179(1):67-77. PubMed ID: 31562570
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
38. GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.
Liang J; Zbieg JR; Blake RA; Chang JH; Daly S; DiPasquale AG; Friedman LS; Gelzleichter T; Gill M; Giltnane JM; Goodacre S; Guan J; Hartman SJ; Ingalla ER; Kategaya L; Kiefer JR; Kleinheinz T; Labadie SS; Lai T; Li J; Liao J; Liu Z; Mody V; McLean N; Metcalfe C; Nannini MA; Oeh J; O'Rourke MG; Ortwine DF; Ran Y; Ray NC; Roussel F; Sambrone A; Sampath D; Schutt LK; Vinogradova M; Wai J; Wang T; Wertz IE; White JR; Yeap SK; Young A; Zhang B; Zheng X; Zhou W; Zhong Y; Wang X
J Med Chem; 2021 Aug; 64(16):11841-11856. PubMed ID: 34251202
[TBL] [Abstract][Full Text] [Related]
39. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
